SAMUEL OKPAKU: Open Payments
NPI 1427070879 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,405 in 26 payments from 9 companies in 2025. Trend: 2023 $1,173 · 2024 $274 · 2025 $1,405
Food & beverage: $1,405
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 8 | $300 |
| Axsome Therapeutics, Inc. | 3 | $259 |
| Alkermes, Inc. | 2 | $245 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $212 |
| E.R. Squibb & Sons, L.L.C. | 3 | $149 |
| Teva Pharmaceuticals USA, Inc. | 1 | $119 |
| Neurocrine BioSciences, Inc. | 2 | $62 |
| ABBVIE INC. | 2 | $47 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
Products named: Auvelity, FANAPT, CAPLYTA, COBENFY, LYBALVI, ARISTADA, AUSTEDO XR, HETLIOZ.
Industry payments across TN — which companies pay providers there.
